The phrase "assessing cancer" is correct and usable in written English.
It can be used in contexts related to medical evaluations, research, or discussions about cancer diagnosis and treatment.
Example: "The team is focused on assessing cancer in patients to determine the most effective treatment options."
Alternatives: "evaluating cancer" or "analyzing cancer".
However, unlike CVD risk assessment, there is some difficulty in assessing cancer risk (except for cases with familial and genetic factors) in clinical practice.
Increasing interest in assessing cancer risk, monitoring disease, predicting recurrence, and determining the efficacy of treatments has coincided with developments in the fields of genomics and proteomics.
"And we know from other areas of toxicology that if you have good biomarkers for predicting carcinogenesis, that can be powerful when thinking about assessing cancer risks.
Over the last few years new insights into how chemicals cause cancer have prompted federal agencies to revise their approaches to assessing cancer risk.
Such an extreme volume difference is found in very few women, says Scutt, who notes that other factors must be taken into account when assessing cancer risk.
This assay has been used in a number of laboratories in the field of epidemiology, where it has been investigated and appears to be a useful susceptibility biomarker for epidemiological studies assessing cancer risks at the population level.
The objectives of this study were to evaluate the reliability, validity, and utility of a newly developed clinical syndrome approach to assessing cancer-related fatigue.
This instrument has been demonstrated to be a brief, valid, and feasible scale for assessing cancer-related dyspnea among inoperable NSCLC patients[ 42, 43].
Because the risk of stroke increases with age (Hollander et al, 2003), age-specific and age-adjusted analyses are required in assessing cancer-related stroke risk.
The highest scores were found in studies assessing cancer-related post-traumatic stress immediately after diagnosis or during treatment, whereas the lowest scores were found in samples of breast cancer survivors assessed up to 15 years post diagnosis.
Assessing cancer-specific mortality relies on precise and correct data on the cause of death; however, these data can be difficult to achieve, particularly in elderly patients where comorbidity is common.
